A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient ... administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...